Skip to main content

Table 5 Late postoperative outcomes of the 70 patients with rectal cancer and synchronous liver metastases according to their management

From: Simultaneous or staged resection for synchronous liver metastasis and primary rectal cancer: a propensity score matching analysis

 

Before matching

After matching

Overall Population

Staged surgery

Simultaneous resection

P

Staged surgery

Simultaneous resection

P

N (%)

70 (100)

48 (69)

22 (31)

-

22 (50)

22 (50)

-

Oncological results

 

Adjuvant chemotherapy, n (%)

56 (80)

38 (79.1)

18 (32.1)

1.000

7 (31.8)

6 (27.3)

0.741

Recurrence, n (%)

51 (72.9)

40 (83.3)

11 (50)

0.0078

18 (81.8)

11 (50)

0.026

Rectal

5 (7.1)

5 (10.4)

0

0.1727

2 (9.1)

0

0.148

Liver

32 (45.7)

26 (54.2)

6 (27.2)

0.0425

14 (63.6)

8 (36.6)

0.070

Carcinosis

11 (15.7)

8 (16.7)

3 (13.6)

1.000

2 (9.1)

3 (13.6)

0.635

Number of recurrences sites, n (%)

 

1

36 (51.4)

26 (54.2)

10 (45.5)

0.5604

16 (88.9)

10 (90.9)

0.862

2

8 (11.4)

7 (14.6)

1 (4.5)

2 (11.1)

1 (9.1)

3

1 (1.4)

1 (2.1)

0

0

0

Time to recurrence (month), median ± IQR

15 (11–20)

17 (11–21)

13 (11–14)

0.3568

13 (6–25)

8 (5–11)

0.465

Median of follow up (months) ± IQR

28 (18–39)

28 (19–42)

20 (13–34)

0.0990

28 (16–38)

16 (8–38)

0.285

Overall survival at 3 years (%)

86%

85%

42%

0.0749

68%

62%

0.517

Overall survival at 5 years (%)

44%

77%

54%

45%

46%

Disease free survival at 3 years (%)

20%

19%

4.5%

0.6851

7%

10%

0.691

Disease free survival at 5 years (%)

3.5%

24%

0%

–

–

Recurrence treatment, n (%)

 

Surgery

11 (15.7)

9 (18.8)

2 (9.1)

0.2998

6 (27.3)

2 (9.1)

0.118

Chemotherapy

39 (55.7)

31 (64.6)

8 (36.4)

0.7063

13 (59.1)

8 (36.4)

0.131

Radiotherapy

11 (15.7)

7 (14.6)

4 (18.2)

0.2220

3 (13.6)

4 (18.2)

0.680

Delayed fistula, n (%)

2 (2.9)

0

2 (9.1)

0.0431

0

0

-

  1. Number in bold correspond to an stastical difference (P < 0.05)
  2. IQR interquartile range